Literature DB >> 2302726

Effect of anticancer drugs on the release of tumour necrosis factor in vitro.

S I Hasan1, K Ahmed, J L Turk.   

Abstract

The anticancer drugs Adriamycin, bleomycin, vincristine, 4-hydroperoxycyclophosphamide, FK156 and FK565 and the immunosuppressive drug cyclosporin-A were tested for their effect on lipopolysaccharide-induced tumour necrosis factor-alpha (TNF) release from rat peritoneal exudate cells in vitro. FK565 resulted in a marked enhancement of TNF release when added to cultures at doses of 1 microgram/ml and 10 micrograms/ml. However, FK156, Adriamycin, bleomycin, 4-hydroperoxycyclophosphamide, vincristine and cyclosporin A did not affect the release of TNF under the same conditions. Puromycin inhibited the release of TNF in the same system at non-cytotoxic doses of 1 microgram/ml and 10 micrograms/ml.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2302726     DOI: 10.1007/bf01786886

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  15 in total

1.  Potentiation of release of interleukin-2 by bleomycin.

Authors:  T A Abdul Hamied; D Parker; J L Turk
Journal:  Immunopharmacology       Date:  1986-10

2.  Effect of anticancer agents neothramycin, aclacinomycin, FK-565 and FK-156 on the release of interleukin-2 and interleukin-1 in vitro.

Authors:  K Ahmed; J L Turk
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Selective cytotoxicity of peritoneal leucocytes for neoplastic cells.

Authors:  O A Holtermann; E Klein; G P Casale
Journal:  Cell Immunol       Date:  1973-12       Impact factor: 4.868

4.  Suppression of delayed-type hypersensitivity reactions and lymphokine production by cyclosporin A in the mouse.

Authors:  A W Thomson; D K Moon; D S Nelson
Journal:  Clin Exp Immunol       Date:  1983-06       Impact factor: 4.330

5.  Immunoactive peptides, FK-156 and FK-565. I. Enhancement of host resistance to microbial infection in mice.

Authors:  Y Mine; Y Yokota; Y Wakai; S Fukada; M Nishida; S Goto; S Kuwahara
Journal:  J Antibiot (Tokyo)       Date:  1983-08       Impact factor: 2.649

Review 6.  Interleukin-1.

Authors:  C A Dinarello
Journal:  Rev Infect Dis       Date:  1984 Jan-Feb

7.  Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2.

Authors:  D Bunjes; C Hardt; M Röllinghoff; H Wagner
Journal:  Eur J Immunol       Date:  1981-08       Impact factor: 5.532

8.  Soluble malarial antigens are toxic and induce the production of tumour necrosis factor in vivo.

Authors:  C A Bate; J Taverne; J H Playfair
Journal:  Immunology       Date:  1989-04       Impact factor: 7.397

9.  Activated macrophages release a factor which lyses malignant cells but not normal cells.

Authors:  G A Currie; C Basham
Journal:  J Exp Med       Date:  1975-12-01       Impact factor: 14.307

10.  Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells.

Authors:  B Beutler; J Mahoney; N Le Trang; P Pekala; A Cerami
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more
  2 in total

1.  Immunoregulatory cytokine release in rat spleen cell cultures after treatment with bleomycin and its analogues in vivo.

Authors:  M Micallef; M Hosokawa; T Shibata; A Nakane; Z B Yang; T Minagawa; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Effect of anticancer drugs on the release of interleukin-6 in vitro.

Authors:  S I Hasan; B A Blaney; J L Turk
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.